What the Anti-C Antibody Targets
The anti-C antibody is an immunoglobulin directed against the C antigen, a protein found on the surface of red blood cells. The C antigen belongs to the Rh blood group system, which is second only to the ABO system in clinical importance for transfusion and pregnancy. Whether a person carries the C antigen depends on their RHD and RHCE gene variants. Individuals who are C-negative can develop anti-C antibodies if exposed to C-positive red blood cells through transfusion or pregnancy.
More from this site
Keep reading the latest coverage
Anti-C is classified as a clinically significant antibody because it can bind complement and coat red cells, marking them for destruction. This leads to hemolysis, which can manifest as a delayed hemolytic transfusion reaction or, during pregnancy, as hemolytic disease of the fetus and newborn. The antibody is typically IgG, which means it crosses the placenta efficiently and can affect the developing fetus even in a first pregnancy.
How Anti-C Antibodies Develop
Alloimmunization occurs when the immune system encounters foreign red cell antigens. For anti-C, the most common triggers are transfusion of C-positive packed red blood cells or fetal-maternal hemorrhage during pregnancy or delivery. The immune response is often anamnestic, meaning it rises rapidly upon re-exposure. A person who is C-negative and has been previously sensitized may produce a brisk anamnestic response that clears C-positive cells from circulation before a transfusion reaction becomes clinically apparent, or it can cause a rapid and severe hemolysis.
Screening for anti-C is part of the antibody identification panel performed in pre-transfusion testing. Laboratories use a panel of reagent red blood cells with known antigen profiles to identify the specificity of unexpected antibodies. Once anti-C is identified, antigen typing of the recipient and donor units becomes essential to provide compatible blood.
Clinical Significance in Transfusion
Transfusion medicine prioritizes the provision of antigen-negative blood when clinically significant antibodies like anti-C are present. For C-negative patients with anti-C, the blood bank issues C-negative, and usually also D-negative and E-negative, units to prevent further alloimmunization. Crossmatching confirms serologic compatibility before the unit is released.
Because anti-C can cause hemolytic transfusion reactions, the antibody titer and strength are monitored in multiply-transfused patients. A rising titer may prompt closer surveillance. In sickle cell disease and thalassemia populations, where chronic transfusion is common, the risk of developing anti-C and other Rh antibodies is elevated, making extended phenotype matching a standard-of-care strategy in many centers.
| Context | Risk Level | Management |
|---|---|---|
| Transfusion reaction | Moderate to severe | Stop transfusion, administer supportive care, confirm antibody specificity |
| Pregnancy (sensitized) | Variable, depends on titer | Serial titers, middle cerebral artery Doppler, possible intrauterine transfusion |
| Chronic transfusion | Cumulative risk | Extended phenotype matching, antigen-negative inventory |
Anti-C and Hemolytic Disease of the Fetus and Newborn
Hemolytic disease of the fetus and newborn, or HDFN, occurs when maternal IgG antibodies cross the placenta and target fetal red cell antigens. Anti-C is a recognized cause of HDFN, though it is less common than anti-D. The severity depends on the antibody titer, the ability to fix complement, and the antigen density on fetal red cells. Affected pregnancies require close monitoring with serial antibody titers and middle cerebral artery peak systolic velocity measurements to detect fetal anemia early.
Management of a pregnancy complicated by anti-C may include intrauterine transfusion, early delivery, or postnatal exchange transfusion depending on the gestational age and severity of anemia. Neonatal follow-up includes monitoring bilirubin levels and hematocrit, as the newborn may continue to hemolyze antibody-coated red cells after birth.
Laboratory Detection and Interpretation
The anti-C antibody is detected during the antibody screening and identification phases of pre-transfusion testing. It typically reacts in the indirect antiglobulin test phase, also called the Coombs test, and is usually enhanced by enzyme-treated panel cells. The antibody is often panreactive with C-positive cells and non-reactive with C-negative cells, providing a clear pattern on the panel that allows for confident identification.
Distinguishing anti-C from other Rh antibodies, such as anti-E or anti-c, requires a panel that includes cells with single antigen differences. Weak D and partial D variants can complicate the serologic picture, but the antibody specificity is determined by the reaction pattern rather than the donor phenotype alone. Confirmatory testing with selected C-positive and C-negative cells solidifies the identification before incompatible units are released.